Job creations
Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer.
Following a change to U.S. corporate tax laws, Pfizer announced at the beginning of this year that it intends to invest $5 billion in U.S. manufacturing over the next five years. On Tuesday, Pfizer showed its commitment to that promise with a $465 million investment in a new Michigan manufacturing site that is expected to create more than 450 jobs.
Teva Pharmaceuticals is moving its U.S. headquarters to Parsippany-Troy Hills, New Jersey as part of a plan to centralize its operations in North America.
Boston, New York, San Diego and San Francisco are the typical spots that people refer to when they think about biotech hotspots in the United States. But don’t discount New Jersey.
Evotec is now a more powerful player in the infectious disease sector following the signing of its three-month-old deal to integrate Sanofi’s anti-infectives unit, including the majority of Sanofi’s infectious disease research portfolio and initiatives into its organization.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
In late March, Novo Nordisk broke ground on a new manufacturing facility in rural Clayton, North Carolina.
In anticipation of marketing approval in Europe, Gilead Sciences has leased a 117,000 square-foot facility in The Netherlands to manufacture and deliver Yescarta, its CAR-T product, to patients across Europe.
Vyriad, based in Rochester, Minnesota, announced it is building out its facility in 25,000 square feet of space it is leasing on the IBM Campus in Rochester.
PRESS RELEASES